Features How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease?
By Malorye Branca SPECIAL REPORT: Resolving Bottlenecks, Part II
Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. By Mark D. Uehling
News·Analysis EDC Shreds Paper TrailsDebating DNA in MontereyNeuroscientists Have Better Tools on the BrainHopkins Takes IBM to HeartFrom Field to Streaming DataGenomic Services Sector Heats UpKinder, Gentler FDA in the Making?Nanotech Sprouts in the Garden State
Bio-IT World Conference & Expo Highlights:Stephen Friend Sees Novel Uses of Gene ChipsIBM’s Kovac on Information-Based MedicineFrancis Collins Nixes Post-Genomic EraBest of Show AwardsHorizonsHonest Jim Watson remains as charming, humorous, obstinate, and outrageous as ever. Scientists strike a chord with music based on the building blocks of DNA. The bio-IT community has a unique opportunity to contribute to national biodefense. Columns & Departments
| Kevin Davies
The world celebrates the golden anniversary of the double helix.
| Michael A. GreeleyAs biotech business models evolve, the question remains: Which will survive?
| By Robert M. FredericksonProtein chips seek to do for protein expression profiling what DNA chips did for RNA expression.
| John Dodge
Complaints aside, EDC has made its mark. All it needs now is a big boot. MEMS the word for Protiveris prototype · RLX doubles up with dual-processor blade server · EMC debuts high-end storage systems